(Q33394065)

English

Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Se-Hoon Lee

3

0 references

8

object named as

Yung-Jue Bang

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

5

object named as

Seock-Ah Im

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

object named as

Do-Youn Oh

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

6

object named as

Tae-You Kim

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

7

object named as

Dae Seog Heo

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Mi-Jung Kim

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dong-Wan Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

18 December 2008

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

374

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Cancer statistics, 2007

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Gemcitabine in advanced biliary tract cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Phase II study of erlotinib in patients with advanced biliary cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Biliary tract cancers: current concepts and controversies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Phase II study of S-1 in patients with advanced biliary tract cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Review of gemcitabine in biliary tract carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Synergistic interaction between cisplatin and gemcitabine in vitro.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Recent advances in the management of cholangiocarcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2615782

21 June 2018

Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-374

21 January 2018

A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-374

21 January 2018

Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-374

21 January 2018

Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-374

21 January 2018

Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-374

21 January 2018

Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-374

21 January 2018

A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-374

21 January 2018

Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-374

21 January 2018

Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19091129

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19091129

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of cisplatin in patients with biliary tract carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19091129

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/19091129

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19091129

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/19091129

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract

1 reference

https://pubmed.ncbi.nlm.nih.gov/19091129

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-8-374

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33394065&oldid=2195318369"